Martingale Asset Management L P Bluebird Bio, Inc. Transaction History

Martingale Asset Management L P

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $202 - $399	54 Added 0.19%	27,967 $178,000
Q4 2021 Feb 11, 2022	BUY	$8.96 - $16.31 $2,688 - $4,893	300 Added 1.09%	27,913 $278,000
Q3 2021 Nov 12, 2021	BUY	$11.24 - $21.0 $161,912 - $302,505	14,405 Added 109.06%	27,613 $341,000
Q2 2021 Aug 13, 2021	BUY	$18.04 - $22.09 $111,884 - $137,002	6,202 Added 88.52%	13,208 $273,000
Q1 2021 May 13, 2021	SELL	$16.59 - $33.89 $114,471 - $233,841	-6,900 Reduced 49.62%	7,006 $136,000
Q4 2020 Feb 10, 2021	SELL	$27.5 - $37.92 $46,750 - $64,464	-1,700 Reduced 10.89%	13,906 $389,000
Q3 2020 Nov 12, 2020	BUY	$34.44 - $43.75 $27,655 - $35,131	803 Added 5.42%	15,606 $545,000
Q2 2020 Aug 10, 2020	BUY	$27.12 - $45.97 $401,457 - $680,493	14,803 New	14,803 $585,000
Q2 2018 Aug 09, 2018	SELL	$99.64 - $127.59 $1.33 Million - $1.7 Million	-13,311 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$105.8 - $150.94 $105 - $150	1 Added 0.01%	13,311 $0
Q4 2017 Feb 12, 2018	SELL	$81.25 - $130.7 $105,300 - $169,387	-1,296 Reduced 8.87%	13,310 $0
Q3 2017 Nov 13, 2017	BUY	$57.74 - $91.42 $843,350 - $1.34 Million	14,606	14,606 $2.01 Million

150

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $708M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.